Pangen Biotech Stock Current Liabilities
| 222110 Stock | KRW 6,000 290.00 4.61% |
PanGen Biotech fundamentals help investors to digest information that contributes to PanGen Biotech's financial success or failures. It also enables traders to predict the movement of PanGen Stock. The fundamental analysis module provides a way to measure PanGen Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PanGen Biotech stock.
PanGen |
PanGen Biotech Company Current Liabilities Analysis
PanGen Biotech's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, PanGen Biotech has a Current Liabilities of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current liabilities for all Republic of Korea stocks is 100.0% higher than that of the company.
Did you try this?
Run Top Crypto Exchanges Now
Top Crypto ExchangesSearch and analyze digital assets across top global cryptocurrency exchanges |
| All Next | Launch Module |
PanGen Fundamentals
| Return On Equity | -24.89 | |||
| Return On Asset | -0.079 | |||
| Profit Margin | (0.92) % | |||
| Operating Margin | (0.82) % | |||
| Current Valuation | 90.89 B | |||
| Shares Outstanding | 9.64 M | |||
| Shares Owned By Insiders | 33.33 % | |||
| Shares Owned By Institutions | 2.47 % | |||
| Price To Sales | 13.35 X | |||
| Revenue | 7.94 B | |||
| Gross Profit | 1.35 B | |||
| EBITDA | (3.07 B) | |||
| Net Income | (3.31 B) | |||
| Cash And Equivalents | 8.9 B | |||
| Total Debt | 5.49 M | |||
| Debt To Equity | 1.52 % | |||
| Current Ratio | 1.12 X | |||
| Cash Flow From Operations | (3.32 B) | |||
| Beta | 0.74 | |||
| Market Capitalization | 59.88 B | |||
| Total Asset | 43.28 B | |||
| Net Asset | 43.28 B |
About PanGen Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PanGen Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PanGen Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PanGen Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with PanGen Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if PanGen Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PanGen Biotech will appreciate offsetting losses from the drop in the long position's value.Moving against PanGen Stock
| 0.87 | 123040 | MS Autotech CoLtd | PairCorr |
| 0.87 | 101400 | N Citron | PairCorr |
| 0.87 | 122690 | Seojin Automotive CoLtd | PairCorr |
| 0.84 | 012700 | LEADCORP | PairCorr |
| 0.84 | 027710 | FarmStory | PairCorr |
The ability to find closely correlated positions to PanGen Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace PanGen Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back PanGen Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling PanGen Biotech to buy it.
The correlation of PanGen Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as PanGen Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if PanGen Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for PanGen Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in PanGen Stock
PanGen Biotech financial ratios help investors to determine whether PanGen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PanGen with respect to the benefits of owning PanGen Biotech security.